Cybin to Participate at the 28th Annual Milken Institute Global Conference
Article content
Article content
– Doug Drysdale, CEO, to appear on panel entitled 'The Global Landscape and Opportunities for Medical Breakthroughs,' on May 5, 2025 –
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 28th Annual Milken Institute Global Conference on a panel entitled 'The Global Landscape and Opportunities for Medical Breakthroughs.' The Conference will take place May 4-7, 2025, at the Beverly Hilton in Los Angeles, and the panel will be held on Monday, May 5, 2025, at 2:30 p.m. PDT.
Article content
'It's truly an honor to return to the Milken Global Conference and to contribute to the discourse around the opportunities we have as drug developers today,' stated Doug Drysdale, Cybin's Chief Executive Officer. 'These are times of extraordinary scientific innovation. We are pushing the boundaries beyond existing standards of care and offering more precise treatment regimens than ever before. As the pace of medical breakthroughs accelerates, Cybin is proud to participate in this extremely important conversation.'
The live panel discussion and archived webcast will be available on the Company's investor relations website on the Events & Presentations page. For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org.
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Article content
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Article content
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Article content
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
Northern Shield Grants Stock Options
OTTAWA, ON, June 6, 2025 /CNW/ - Northern Shield Resources Inc. (" Northern Shield" or the " Company") (TSXV: NRN) announces that it has granted options to acquire a total of 2,220,000 common shares in the capital of the Company (" Common Shares") to its directors and officers and a further 210,000 to employees and consultants pursuant to its shareholder approved stock option plan (the " Stock Option Plan"). Each option entitles the holder to acquire one Common Share at an exercise price of $0.12 per Common Share until June 6, 2030. Following such grant, Northern Shield now has outstanding under its Stock Option Plan, options to acquire Common Shares equal to just under 8% of Northern Shield's currently outstanding Common Shares. About Northern Shield Resources Northern Shield Resources Inc. is a Canadian-based company known as a leader in generating high-quality exploration targets that views greenfield exploration as an opportunity to find a mineable deposit, near surface, and at relatively low cost. We implement a model driven exploration approach to reduce the risk associated with early-stage projects for ourselves, our shareholders, and the environment. This approach led us to option the Root & Cellar Property from a Newfoundland prospector, who discovered the mineralization, and then its advancement to a large gold-silver-tellurium system. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
a day ago
- Cision Canada
Minsud Announces Option Grant
TORONTO, June 6, 2025 /CNW/ - Minsud Resources Corp. (TSXV: MSR) (" Minsud" or the " Company") is pleased to announce that it has granted options to purchase an aggregate of 600,000 common shares of the Company (the " Stock Options") to certain directors of the Company. The Stock Options are exercisable at a price of $0.60 per share for a period of five years from the date of issuance. As of the date hereof, a total of 16,494,852 common shares of the Company are reserved for issuance under the Company's stock option plan and, after this new grant, 13,876,000 options will be outstanding. About Minsud Resources Corp. Minsud is a mineral exploration company focused on exploring its flagship Chita Valley Cu-Mo-Au-Ag-Pb-Zn Project, in the Province of San Juan, Argentina. The Company's shares are listed on the TSX-V under the trading symbol "MSR", and on the OTCQX under the symbol "MDSQF". Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Minsud Resources Corp.
Cision Canada
a day ago
- Cision Canada
Graham Rosenberg Proposed Sale of Shares
TORONTO, June 6, 2025 /CNW/ - Graham Rosenberg (the "Selling Shareholder"), the Chief Executive Officer and Chairman of the Board of dentalcorp Holdings Ltd. (the "Company"), announces that he has filed a notice of intention to distribute securities in connection with the his intention to sell, directly or indirectly, up to 477,700 subordinate voting shares of the Company ("SVS"), 450,000 of which will be issued upon the conversion of multiple voting shares of the Company ("MVS" and together with the SVS, the "Shares") in accordance with their terms (the "Sale"). After the Sale, Mr. Rosenberg will, directly or indirectly, retain over 95% of his securities in the Company, including 100% of the Company's issued and outstanding MVS. Mr. Rosenberg plans to use the proceeds from the Sale for tax, financial and estate planning purposes. A copy of the Form 45-102F1 – Notice of Intention to Distribution Securities under Section 2.8 of National Instrument 45-102 – Resale of Securities filed by the Selling Shareholder is available under the Company's profile on the System for Electronic Document Analysis and Retrieval + ("SEDAR+") at There is no assurance as to the timing of the proposed transactions thereunder nor whether any such transactions will occur. Required Early Warning Disclosure This additional disclosure is being provided pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed by GR BCM2 #2 Acquisition Limited Partnership (the "Partnership") with the regulatory authorities in each jurisdiction in which the Company is a reporting issuer containing information with respect to the conversion of MVS to SVS in accordance with their terms (the "Conversion") to be completed in connection with the Sale (the "Early Warning Report"). Prior to the Conversion, Mr. Rosenberg, directly or indirectly, through entities owned and/or controlled, directly or indirectly by him, including the Partnership (the "Rosenberg Group"), held 8,704,535 MVS, representing 100% of the issued and outstanding MVS or 31.5% of the votes attached to all of the Company's issued and outstanding Shares, and 93,774 SVS, representing 0.05% of the issued and outstanding SVS or 0.03% of the votes attached to all of the Company's issued and outstanding Shares. In addition, Mr. Rosenberg held 168,582 restricted share units ("RSUs"), 225,629 performance share units ("PSUs") and 2,750,000 options ("Options"), each exercisable or settled for SVS. Following the Conversion, the Rosenberg Group held 8,254,535 MVS, representing 100% of the issued and outstanding MVS or 30.3% of the votes attached to all of the Company's issued and outstanding Shares, and 543,774 SVS, representing 0.29% of the issued and outstanding SVS or 0.20% of the votes attached to all of the Company's issued and outstanding Shares. Mr. Rosenberg intends to sell, directly or indirectly through the Partnership, up to 477,700 SVS pursuant to the Sale. In addition, Mr. Rosenberg continues to hold 168,582 RSUs, 225,629 PSUs and 2,750,000 Options, each exercisable or settled for SVS. Each MVS represents ten votes on all matters upon which holders of shares in the capital of the Company are entitled to vote and is convertible into one SVS at any time at the sole option of the holder. In addition to the Sale, the Rosenberg Group may, depending on market conditions, acquire additional SVS or dispose of MVS or SVS in the future whether in transactions over the open market or through privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and investment diversification. The Company's head office is located at 181 Bay Street, Suite 2600, Toronto, Ontario, M5J 2T3. A copy of the Early Warning Report will be filed under the Company's profile on SEDAR+. The head office of the Selling Shareholder is 181 Bay Street, Suite 2600 Toronto, Ontario M5J 2T3.
